Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial
Authors:
Open Access
- 8 January 2015
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 15 (1) , 1-11
Abstract
Although mouse brain-derived, inactivated Japanese encephalitis vaccines (JE-MBs) have been successfully used for a long time, potential rare neurological complications have prompted the development of a Vero cell culture-derived inactivated vaccine (JE-VC). In a phase III clinical study, we aimed to compare the safety and immunogenicity of a JE-VC, KD-287 with a JE-MB, JEV-GCC, in children. In this multicenter, double-blinded, randomized controlled trial, the study population consisted of 205 healthy Korean children aged 12–23 months. Each subject was subcutaneously vaccinated with either KD-287 or JEV-GCC twice at an interval of 2 weeks and then vaccinated once 12 months after the second vaccination. Neutralizing antibodies were measured by the plaque reduction neutralization test using the homologous and heterologous, as a post hoc analysis, challenge virus strains. The three-dose regimen of KD-287 showed a comparable safety profile with JEV-GCC except higher incidence of fever after the first dose (30.4% and 14.7%, respectively). Most of the fever was mild degree (61.3% and 66.7%, respectively). KD-287 fulfilled the non-inferiority criteria for seroconversion rate (SCR) and geometric mean titer (GMT) of the neutralizing antibody, which were the primary endpoints, at 4 weeks after the third vaccination (95% CI: −1.00, 3.10 for the SCR difference and 10.8, 17.6 for the GMT ratio). The SCRs of KD-287 were all 100% and the GMTs were higher in the KD-287 group than in the JEV-GCC group after the second vaccination and before and after the third vaccination (GMT ratio: 5.59, 20.13, and 13.79, respectively, p < 0.001 in all). GMTs were higher in the KD-287 group in the heterologous analysis also (GMT ratio: 4.05, 5.15, and 4.19, respectively, p < 0.001 in all). This study suggests that the KD-287, a JE-VC is as safe as and may be more effective than the licensed MB-derived vaccine. KD-287 could thus be useful as a second-generation vaccine and substitute for the current JE-MB vaccine in Korean children. ClinicalTrials.gov: NCT01150942Keywords
This publication has 31 references indexed in Scilit:
- A Single Dose of Vero Cell-Derived Japanese Encephalitis (JE) Vaccine (Ixiaro) Effectively Boosts Immunity in Travelers Primed With Mouse Brain-Derived JE VaccinesClinical Infectious Diseases, 2012
- Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated)Vaccine, 2012
- The history of vaccination and current vaccination policies in KoreaClinical and Experimental Vaccine Research, 2012
- Emergence of Japanese encephalitis virus genotype V in the Republic of KoreaVirology Journal, 2011
- Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51Vaccine, 2011
- Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51Vaccine, 2010
- Randomized, Double‐Blind, Placebo‐Controlled Phase 3 Trial of the Safety and Tolerability of IC51, an Inactivated Japanese Encephalitis VaccineThe Journal of Infectious Diseases, 2008
- Current use and development of vaccines for Japanese encephalitisExpert Opinion on Biological Therapy, 2007
- Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan childrenJournal of Medical Virology, 1994
- Protection against Japanese Encephalitis by Inactivated VaccinesNew England Journal of Medicine, 1988